Bnai Zion
Haifa, Israel
NCT Number: NCT02373852
The objective of this study is to collect data on the use of the WIRION system in Patients undergoing Percutaneous Intervention of Saphenous Vein Graft (SVG).
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Haifa, Israel
WIRION system is used as protection device in patients undergoing SVG stenting procedure. This retrospective study collects data on the usability of the WIRION during the procedure.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Opening and stenting of blocked SVG with the use of the WIRION embolic protection filter
Time frame: 30 Days
Collect and analyse all adverse events occurred during and following the SVG procedure up to 30 days.
Time frame: 30 Days
Successful procedure is considered as a procedure in which no distal embolization, dissection, perforation, abrupt closure or no reflow occurred.
Gardia Medical
Industry
Post Marketing Surveillance (PMS) Retrospective Study of WIRION Performance in Patients Undergoing Saphenous Vein Graft (SVG) Intervention
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06986954
Aneurysm, False, Bleed Intracranial
Darien, Connecticut, United States
View Trial DetailsNCT05053932
Anemia, Anemia, Hemolytic
Paris, IDF, France
View Trial DetailsNCT05566704
Bone Diseases, Constriction, Pathologic
Orange, California, United States
View Trial DetailsNCT05268445
Aneurysmal Subarachnoid Hemorrhage, Arteriovenous Fistula
Brussels, Belgium
View Trial Details